The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Insmed Inc (NASDAQ: INSM) was $163.72 for the day, down -2.38% from the previous closing price of $167.72. In other words, the price has decreased by -$2.38 from its previous closing price. On the day, 3.74 million shares were traded. INSM stock price reached its highest trading level at $170.45 during the session, while it also had its lowest trading level at $162.3.
Ratios:
Our analysis of INSM’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.34 and its Current Ratio is at 4.63. In the meantime, Its Debt-to-Equity ratio is 0.79 whereas as Long-Term Debt/Eq ratio is at 0.77.
On December 04, 2025, Rothschild & Co Redburn started tracking the stock assigning a Buy rating and target price of $263.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 12 ’26 when Lewis William sold 19,215 shares for $169.00 per share. The transaction valued at 3,247,349 led to the insider holds 306,891 shares of the business.
Flammer Martina M.D. sold 1,887 shares of INSM for $351,341 on Jan 09 ’26. The Chief Medical Officer now owns 84,907 shares after completing the transaction at $186.19 per share. On Jan 12 ’26, another insider, William Lewis, who serves as the Officer of the company, bought 19,215 shares for $169.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INSM now has a Market Capitalization of 34917134336 and an Enterprise Value of 33977280512. For the stock, the TTM Price-to-Sale (P/S) ratio is 78.11 while its Price-to-Book (P/B) ratio in mrq is 36.81. Its current Enterprise Value per Revenue stands at 76.008 whereas that against EBITDA is -34.714.
Stock Price History:
The Beta on a monthly basis for INSM is 1.10, which has changed by 1.3891737 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, INSM has reached a high of $212.75, while it has fallen to a 52-week low of $60.40. The 50-Day Moving Average of the stock is -13.57%, while the 200-Day Moving Average is calculated to be 26.94%.
Shares Statistics:
INSM traded an average of 2.93M shares per day over the past three months and 2618360 shares per day over the past ten days. A total of 212.58M shares are outstanding, with a floating share count of 210.33M. Insiders hold about 1.38% of the company’s shares, while institutions hold 100.33% stake in the company. Shares short for INSM as of 1767139200 were 11015687 with a Short Ratio of 3.76, compared to 1764288000 on 9866791. Therefore, it implies a Short% of Shares Outstanding of 11015687 and a Short% of Float of 5.71.
Earnings Estimates
The firm’s stock currently is rated by 13.0 analysts. The consensus estimate for the next quarter is -$1.03, with high estimates of -$0.68 and low estimates of -$1.63.
Analysts are recommending an EPS of between -$4.97 and -$6.92 for the fiscal current year, implying an average EPS of -$6.06. EPS for the following year is -$3.28, with 14.0 analysts recommending between -$1.95 and -$5.36.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 13 analysts. It ranges from a high estimate of $264.11M to a low estimate of $166.92M. As of. The current estimate, Insmed Inc’s year-ago sales were $104.44MFor the next quarter, 13 analysts are estimating revenue of $233.34M. There is a high estimate of $286.91M for the next quarter, whereas the lowest estimate is $185M.
A total of 15 analysts have provided revenue estimates for INSM’s current fiscal year. The highest revenue estimate was $606.75M, while the lowest revenue estimate was $509.5M, resulting in an average revenue estimate of $549.88M. In the same quarter a year ago, actual revenue was $363.71MBased on 17 analysts’ estimates, the company’s revenue will be $1.29B in the next fiscal year. The high estimate is $1.67B and the low estimate is $1.03B.
